| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lignan found in bark of some magnolia species. Magnolol (MAG) — a bioactive biphenolic compound from Magnolia officinalis derived from the bark (roots and branches) of Magnolia species such as M. officinalis, M. obovata, and M. grandiflora The two main bioactive compounds isolated from these plants are MAG (5,5ʹ-diallyl-2,2ʹ-dihydroxybiphenyl) and Honokiol (3,5ʹ-diallyl-4,2ʹ-dihydroxybiphenyl) (Fig. 1) which are phenolic regioisomers. In the bark extracts of Magnolia plants, the composition of MAG ranges from 1 to 10%, while Honokiol comprises 1 to 5% Magnolol is a biphenolic neolignan isolated from the bark of Magnolia officinalis. It is structurally related to honokiol and is studied for anti-inflammatory, antioxidant, antimicrobial, and neuroactive effects. In preclinical oncology models, magnolol is reported to modulate NF-κB, STAT3, PI3K/AKT, MAPK, Wnt/β-catenin, and redox pathways, with downstream effects on cell-cycle arrest, apoptosis, invasion/EMT, and angiogenesis. Oral bioavailability is limited and many cytotoxic concentrations reported in vitro are in the tens of µM range, often above typical systemic levels from standard supplementation. major pathways and molecular targets involved in magnolol’s anticancer actions: -Apoptosis: ↑ Bax, ↓ Bcl-2, ↑ cytochrome c, ↑ caspase-9, ↑ caspase-3 -Arrests cell cycle at G0/G1 or G2/M phase:↓ Cyclin D1, CDK4, CDK6, Cyclin B1, CDK1 -Inhibits NF-κB activation: ↓ IκBα, COX-2, TNF-α -Inhibits PI3K, Akt, and mTOR phosphorylation -Suppresses angiogenesis: ↓ Bcl-XL, Mcl-1, VEGF, cyclin D1 -Inhibits β-catenin nuclear translocation -increase ROS production in tumor cells → triggers mitochondrial apoptosis -Magnolol activates Nrf2 in normal cells → upregulates HO-1, NQO1: Protects normal tissue from oxidative stress during chemotherapy or inflammation. Most in-vitro IC50 values fall in the 10–100 µM range, often above typical systemic exposure.
Time-Scale Flag (TSF): P / R / G
|
| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 5252- | MAG, | Insights on the Multifunctional Activities of Magnolol |
| - | Review, | Var, | NA |
| 4533- | MAG, | Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways |
| - | in-vitro, | GC, | SGC-7901 |
| 4535- | MAG, | 5-FU, | Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways |
| - | in-vitro, | Cerv, | NA |
| 972- | MAG, | Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells |
| - | vitro+vivo, | Bladder, | T24/HTB-9 |
| 4519- | MAG, | Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 4515- | MAG, | Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight |
| - | Review, | Var, | NA |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 1089- | MAG, | Magnolol potently suppressed lipopolysaccharide-induced iNOS and COX-2 expression via downregulating MAPK and NF-κB signaling pathways |
| - | in-vitro, | AML, | RAW264.7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:121 Target#:4 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid